Research Projects and Community Programs


Research Gate

research-gate

http://www.researchgate.net/researcher/38177022_Anoop_Misra


  • Genetic studies of fatty liver and fat free mass, ICMR, Rs. 20 lacs, 2009.
  • Trans Fatty Acids: Effects of Insulin Resistance and Lipids, DST, Rs. 20 lacs, 2009.
  • Autologous stem cell trail in diabetic foot, 2009.
  • Investigations of lean phenotype of diabetes in Asian Indians. A multi-site collaborative study, Investigator-initiated grant, MSD, 2009.
  • Intervention trial of almonds in patients with type 2 diabetes, Rs. 30 lacs, Almond Board of California.
  • Clinical Research: Sugar free Ice cream in Diabetic (Type-2) subjects, Mother Dairy & Vegetables Pvt. Ltd., R. 5 lacs, 2008.
  • To study the validity of bioelectrical impedance for assessment of body composition in Asian Indians, Rs. 9 lacs, 2008.
  • Health Effects of Pistachio nuts, Rs. 40 lacs, 2008.
  • Trends in knowledge, attitude and practice of nutrition in schoolchildren and their parents (Project TEACHER), Rs. 30 lacs, 2006-9.
  • Targeted Intervention in Schoolchildren for Prevention of Obesity and Diabetes, World Diabetes Foundation, Denmark, US $ 1,70, 000, 2005-10.
  • Randomised trial of Fenofibrate in the metabolic syndrome, Rs. 6 lacs, 2007.
  • To Study the Effect of a Protein, Multiple fiber Micronutrient Fortified Supplement on Diabetic Patients, Rs. 5 lacs 2005-7.
  • Double blind randomized placebo-controlled clinical trial of herbal compound MA-579 in patients with non alcoholic fatty liver diseases, Maharishi Ayurveda Products, Rs. 3 lacs, 2005-7.
  • Health Education in school children with reference to obesity, diabetes, nutrition and physical activity (Project CHETNA), Rs. 7 lacs, 2006-8.
  • Double blind randomized placebo-controlled clinical trial of herbal compound MA-471 on metabolic profile of Type 2 diabetic patients, Maharishi Ayurveda Products, Rs. 3.75 lacs, 2005-7.
  • Evaluation of efficacy and safety of Wosulin Biphasic (Human Insulin Biphas regular. NPH, 30:70) (rDNA origin) for control of hyperglycemia in subjects with type 2 diabetes mellitus-phase IV study, Wockhardt Pharmaceutical Company, Rs. 2. 26lacs, 2005-6.
  • Investigation of genetic basis, and gene-lifestyle interactions in generalized and regional obesity and insulin resistance in Asian Indians, Department of Biotechnology, Government of India, Rs 70 lacs (US $140,000), 2004-8.
  • A country-wide survey of nutrition disorders related to non-communicable disease in elderly women (A Multi-site 10 center Study). Department of Science and Technology, Ministry of Science and Technology, Government of India. Rs. 20 lacs (Us $ 40,000), 2004-8.
  • Genetic polymorphism of cholesterol ester transfer protein (CETP) and its association with HDL-c levels in healthy Indian subjects, Submitted to Indian Council of Medical Research, Rs 10 lacs ($ 20,000), 2004-7.
  • A population based study of diabetes and metabolic correlates of cardiovascular risk factors among Asian Indians (Multi-site International Collaboration Study), Texas A&M University subcontracted by CDC, Atlanta, GA, USA, Rs. 20 lacs (US $ 40,000), 2004 -
  • Assessment of nutritional and antioxidant enzyme status in mechanically ventilated critically III patients. Effect on mortality and strategies for improving nutritional support. Department of Science and Technology, Ministry of Science and Technology, Government of India, Rs. 31 lacs, 2003 -
  • Estimation of prevalence of hyperinsulinemia, hyperlipidemia, hypertension, obesity and glucose intolerance and their correlation to nutrition status (with special reference to amount and type of dietary fat and fibre intake), and other lifestyle factors in urban adolescent and young adult population, Department of Science and Technology, Ministry of Science and Technology, Government of India, Rs. 14 lacs, 2000 -04.
  • Study of the relationships between growth hormone-insulin like growth factor-1 axis and hypothalamo-pituitary-adrenal axis with body composition, insulin sensitivity, subclinical inflammation and cytokines in Asian Indians, Department of Science and Technology, Ministry of Science and Technology, Government of India, Rs. 9 lacs, 2004 -
  • Strategies for prevention and management of medical problems in post-menopausal women of urban slums with particular reference to nutrition, osteoporosis, cataract, and hypertension, Department of Science and Technology, Ministry of Science and Technology, Government of India, Rs. 9 lacs, 2000-02.
  • Experimental and clinical evaluation of herbal anti-diabetic compound formulation 'Amree Plus' for its mode of action and toxicity, AIMIL pharmaceutical company, Rs. 6 lacs, 2001 -
  • Open randomized clinical trial comparing Ayurvedic herbal compound, lipomap (MA-1596) with lovastatin in hypercholesterolemia subject, Maharishi Ayurveda Products, Rs. 4 lacs, 2000 -
  • Double blind randomized placebo controlled clinical trial of herbal compound MA-471 on metabolic profile in diabetic patients, Maharishi Ayurveda Products, Rs. 2 lacs, 2001 -
  • Correlation of polymorphism of apolipoprotein E gene with dyslipidemia and body composition Northern Indian subject, Indian Council of Medical Research, Rs. 3 lacs, 2001 -
  • Prospective Open Trial of Sultamicillin Tosylate in Acute Lower Respiratory Tract Infections, Unichem Labs, Rs. 80,000, 1997-98.
  • Chromium status in obesity, hypertensive and NIDDM patients, All India Institute of Medical Sciences, Rs. 30,000, 1997.
  • Apolipoprotein B polymorphisms in hyperlipidemia, National Institute of Communicable Diseases, 1997.
  • Comprehensive public health education campaign on medical and socio-economic aspects of chronic non-communicable disease (hypertension, diabetes mellitus, lipid disorders, obesity and coronary artery disease) in slum dwellers of New Delhi, Department of Science and Technology, Ministry of Science and Technology, Government of India, Rs. 5 lacs, 1997-2000.
  • Evaluation of Lovastatin in patients with Hypercholesterolemia (Multicentre trial), Ranbaxy Labs, Rs. 50,000, 1995-96.
  • Double Blind Randomized Trial of Baralgan with Analgin, Hoechst (Drug Controller of India), Rs. 6 lacs, 1995-97.
  • Insulin clearance in essential hypertension with or without obesity, All India Institute of Medical Sciences, Rs. 30,000, 1995-96.
  • Monitoring of Adverse Drug Reactions (Multicentre trial), Ministry of Health & Family Welfare (Drug Controller of India), Rs. 6 lacs, 1992-97.
  • Clinical study of Losartan, a New Antihypertensive Belonging to a Novel Class-Angiotensin II Receptor Antagonists, in Mild to Moderate Hypertension, Ranbaxy Laboratories, Rs. 80,000.
  • Phase I trial of OFSH vaccine for male contraception. (Multicentre), Department of Biotechnology, IISC-AIIMS, Rs. 10 lacs, 1992-95.
  • Evaluation of safety and efficacy of wosulin biphasic (Human Insulin Biphasic, Regular/NPH, 30:70) (rDNA origin) for control of hyperglycemia in subjects with type 2 diabetes mellitus (Phase IV study), Wockhardt Pharmaceutical Company, Rs. 2 lacs.